Neuroendocrine tumours are rare tumours that develop from neuroendocrine cells. These cells have the traits of hormone-producing cells and nerve cells. They are found all over the body. Symptoms depend on the site and the type of neuroendocrine tumour. Most neuroendocrine tumours have somatostatin receptors which can be detected on the Ga68-dotapeptide scan. Patients with advanced and non-operable neuroendocrine tumours that show uptake on the dotapeptide scans can be treated with Lu-177 Dotatate therapy or peptide receptor radionuclide therapy (PRRT). Our department was one of the first in the region to offer this treatment option and our experience dates back to 2012. Our research activities include the long term follow up of our patients to evaluate the outcomes and improve patient selection. We are also involved in trials in collaboration with our radiation and medical oncologists looking at the use of dotapeptide scans and therapy in other somatostatin positive tumours such as nasopharyngeal carcinoma.
Please contact Prof David Ng Chee Eng, email: [email protected] for more information.
Publications:
